NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalization of minimally invasive procedures, and a decisive consumer shift away from surgery toward faster, lower-risk treatments. Now a powerful new catalyst has arrived from an unexpected direction, the explosion in GLP-1 weight-loss drugs, which is reshaping demand across the entire aesthetics landscape. Active companies from around the markets with current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Establishment Labs Holdings Inc. (NASDAQ: ESTA), Evolus, Inc. (NASDAQ: EOLS), InMode Ltd. (NASDAQ: INMD), and AbbVie Inc. (NYSE: ABBV).

The GLP-1 effect has become one of the most talked-about dynamics in the sector. As millions of patients lose weight rapidly on obesity drugs, many are left with facial volume loss and loose skin, a phenomenon the industry has come to call Ozempic® face, along with sagging elsewhere on the body. That has translated into rising demand for dermal fillers, body-contouring devices, skin-tightening treatments, and other procedures aimed at restoring volume and firmness. With the obesity-drug market projected to reach roughly US$100 billion in annual sales by 2030, the pool of patients who may seek aesthetic follow-up treatments is expanding faster than almost anyone anticipated. More background on the sector is available through Equity Insider.

Within that broad market, one of the most closely watched frontiers is regenerative aesthetics, the effort to move beyond simply filling or tightening tissue toward helping the body rebuild its own. Traditional dermal fillers and biostimulators address the symptoms of aging and volume loss; a newer wave of research is focused on biologic scaffolds and extracellular-matrix technologies that aim to support the body's own tissue regeneration. If that approach proves out, proponents argue it could open an entirely new category within aesthetics, one focused on restoration rather than temporary correction. It is an early-stage and still largely preclinical field, but it is drawing attention precisely because the aesthetics market has shown it will reward genuine innovation.

A Preclinical Company Positioned at the Regenerative Frontier

Conexeu Sciences Inc. (Nasdaq: CNXU) is a preclinical regenerative-tissue and medical-device company working at that regenerative frontier, developing collagen-based scaffold technology intended for applications across medical aesthetics, including facial rejuvenation and body restoration. Rather than competing head-on with established fillers or devices, the company is pursuing an extracellular-matrix approach designed to support the body's own tissue, positioning itself within the emerging regenerative-aesthetics theme rather than the mature injectable or biostimulator categories.

Points that place the company within the sector's current themes include:

• A focus on regenerative, scaffold-based technology, aligning the company with the aesthetics industry's move toward restoration and tissue regeneration rather than temporary correction alone.
• A stated interest in body-restoration and facial-rejuvenation applications, areas of aesthetics seeing heightened demand amid the GLP-1-driven wave of post-weight-loss patients.
• A public listing on the Nasdaq under the symbol CNXU, giving public-market investors direct exposure to an early-stage regenerative-aesthetics story.
• A preclinical, investigational profile, meaning its technology is being advanced through development rather than being marketed or sold, which places it among the earliest-stage, highest-risk participants in the sector.

As a preclinical company, Conexeu carries the risks that come with that status: its technology is investigational, has not received regulatory clearance or approval, generates no revenue, and must advance through extensive testing, regulatory review, and financing before it could reach the market, if it ever does. Those are substantial uncertainties, and they place the company at the speculative end of the aesthetics spectrum, in contrast to the commercial-stage companies that dominate the sector's revenue.

Continued... Read this and more news for Conexeu Sciences Inc. (Nasdaq: CNXU) at: https://equity-insider.com/pages/conexeu-cnxu/

In other industry developments and happenings in the market this week include:

Establishment Labs Holdings Inc. (Nasdaq: ESTA)

Establishment Labs is a medical-technology company focused on breast and body aesthetics and reconstruction, best known for its Motiva® family of implants and a growing minimally invasive product line. Its focus on breast and body applications makes it one of the more relevant reference points for the tissue-and-contouring end of the aesthetics market that regenerative approaches are also targeting.

Establishment Labs has been among the aesthetics names explicitly cited as positioned to benefit from patients seeking body and skin treatments following GLP-1-driven weight loss, and it continues to expand internationally and in the United States. It is referenced only as market and sector context, a far larger and commercial-stage company compared with a preclinical developer, and its results are not indicative of the featured company's prospects.

Evolus, Inc. (Nasdaq: EOLS)

Evolus is a performance-beauty company built around its flagship neurotoxin Jeuveau®, which has been described as one of the fastest-growing botulinum toxin products in the U.S. aesthetics market, and it has been expanding into dermal fillers to broaden its portfolio. It represents the injectable end of the aesthetics market, the established category that regenerative approaches are positioned alongside rather than within.

Evolus has guided to continued double-digit revenue growth and has pointed to rising filler demand, including from patients addressing facial volume loss after rapid weight loss, as a tailwind. It is referenced solely as sector context, a commercial-stage company at a completely different stage from the featured company, and not as a peer or financial comparable.

InMode Ltd. (Nasdaq: INMD)

InMode designs and markets energy-based medical devices for aesthetic and medical treatments, with a portfolio spanning body contouring, skin tightening, and minimally invasive procedures. Its device-based approach to tightening and contouring addresses the same post-weight-loss skin-laxity demand that is reshaping the sector, making it a useful reference for the energy-device category.

InMode has cited GLP-1-related demand for skin-tightening and body-contouring treatments as a factor in its business, while contending with a more cautious capital-equipment spending environment among providers. It is referenced only as market and sector context, a far larger and profitable commercial-stage company compared with a preclinical developer, whose results are not indicative of the featured company's prospects.

AbbVie Inc. (NYSE: ABBV)

AbbVie is a global biopharmaceutical company whose Allergan Aesthetics division is the dominant force in medical aesthetics, home to Botox® Cosmetic, the Juvederm® filler family, and CoolSculpting® body contouring. As the sector's largest and most established player, with aesthetic product sales measured in the billions, it defines the commercial landscape any new entrant is measured against.

AbbVie has continued to innovate across its aesthetics portfolio, including recent regulatory milestones for new injectable products, and remains the reference point for scale and physician confidence in the category. It is referenced purely as market and sector context, an enormously larger and diversified company operating at a vastly different scale from the featured company, and not as a comparable.

Why the Aesthetics Boom Reaches All the Way to the Preclinical Frontier

What connects these companies is a single market reality: aesthetic medicine is growing quickly, its demand base is broadening thanks to demographic and now pharmacological tailwinds, and the sector has repeatedly rewarded innovation that gives patients better, longer-lasting, or more natural results. That environment pulls capital and attention across the full spectrum, from the large-cap incumbents and commercial-stage device and injectable makers that generate the sector's revenue today, to the early-stage and preclinical companies pursuing the regenerative technologies that could define its next category. The GLP-1 wave, the shift toward minimally invasive procedures, and the search for regenerative solutions all point in the same direction, even as the sector spans wildly different levels of maturity and risk.

For preclinical participants, that backdrop is opportunity and risk in equal measure. Early-stage medical-device and biologic companies are highly speculative, face long and uncertain regulatory pathways, generate no revenue, depend on continued financing, and may never bring a product to market. This commentary describes a sector and the companies active within it, and is not a prediction about any company's stock or a recommendation of any kind. But with aesthetics demand accelerating and the industry actively searching for its next category, the regenerative frontier is a corner of the market worth following through Equity Insider as it develops.

Track the Signals Before the Crowd

The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.

Equity Insider | editor@equity-insider.com

DISCLAIMER

Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation, and no communication from us should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are neither licensed nor qualified to provide investment advice. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform their own research and due diligence and to consult a licensed financial professional before considering any level of investing in stocks.

This article is being distributed by Equity Insider, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. MEL has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). MEL also expects to receive further compensation in the future as part of an ongoing digital media effort to increase visibility for the company. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG.

MEL and its owner(s) and operator(s) do not own any shares of Conexeu Sciences Inc., but reserve the right to buy and sell shares of Conexeu Sciences Inc. at any time without any further notice commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of Conexeu Sciences Inc. and may liquidate their shares, which could have a negative effect on the price of the stock.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This document is governed by the laws of Ireland.

References to Establishment Labs Holdings Inc., Evolus, Inc., InMode Ltd. and AbbVie Inc. are provided solely as market and sector context. Those companies are not peers, competitors, or financial comparables of Conexeu Sciences Inc. They are at materially different stages of development and scale, are commercial-stage companies with marketed products and revenue whereas the profiled company is preclinical with none, and their products, revenue, and share performance are not indicative of Conexeu Sciences Inc.'s prospects. No partnership, affiliation, sponsorship, or endorsement is implied, and none of them has any involvement in Conexeu Sciences Inc., this article, or its distribution. Market size figures cited are third-party estimates and projections that vary materially by source and are not presented as addressable revenue for any company named.

Readers are cautioned that investing in preclinical and development-stage medical-device and biologic companies is highly speculative and carries a high degree of risk. Conexeu Sciences Inc. is a preclinical company: its technology is investigational, has not been cleared or approved by the U.S. Food and Drug Administration or any other regulator, generates no revenue, and must advance through extensive preclinical and clinical testing, regulatory review, and additional financing before it could potentially reach commercialization, which it may never achieve. Statements regarding its technology, applications, and future plans are the company's expectations and disclosures, not achieved results, and are sensitive to regulatory, clinical, financing, competitive, and commercialization risks. Please refer to the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov for the assumptions and risk factors associated with its disclosure.

Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies (including the development and potential applications of the company's regenerative-tissue and scaffold technology) and are generally preceded by words such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "plans", "potential" or similar expressions. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected, including regulatory, clinical, financing, competitive, and commercialization risks, and other risks disclosed in the company's filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made as of the date hereof, and Equity Insider undertakes no obligation to update them except as required by law.

Trademarks

Motiva® is a registered trademark of Establishment Labs Holdings Inc. Jeuveau® is a registered trademark of Evolus, Inc. Botox® Cosmetic and Juvederm® are registered trademarks of AbbVie Inc. / Allergan Aesthetics. CoolSculpting® is a registered trademark of AbbVie Inc. Ozempic® is a registered trademark of Novo Nordisk A/S. All third-party trademarks, trade names, and product names referenced in this article are the property of their respective owners and are used for identification and informational purposes only. Their use does not imply any affiliation with, endorsement by, or sponsorship of Conexeu Sciences Inc. or the publisher.

Article Sources:

[1] Company disclosures of Conexeu Sciences Inc. regarding its regenerative-tissue and collagen-based scaffold technology, aesthetics applications, and Nasdaq listing, at www.conexeu.com.

[2] Medical aesthetics market size and growth estimates (approximately US$22–$23 billion in 2026, projected to approximately US$40 billion by 2031 at a CAGR near 12 percent) are drawn from third-party market-research publications, including Grand View Research, Fortune Business Insights, and Mordor Intelligence. Figures vary materially by source, definition, and methodology.

[3] The projection that the global obesity / GLP-1 drug market could reach roughly US$100 billion in annual sales by 2030 reflects third-party analyst and market-research estimates, including published forecasts from Goldman Sachs Research and industry analysts. Such projections are estimates only and are subject to change.

[4] Public disclosures and market data of the referenced companies (Establishment Labs Holdings, Evolus, InMode, and AbbVie), and industry reporting on the GLP-1 and post-weight-loss demand dynamic and injectable, device, biostimulator, and regenerative aesthetics trends, as cited in the body of this article.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-wave-of-weight-loss-drugs-is-quietly-creating-a-multi-billion-dollar-opportunity-that-aesthetic-medicine-is-racing-to-capture-302866509.html

SOURCE Equity Insider